Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Lambertini, M, Kroman, N, Ameye, L, Cordoba, O, Pinto, A, Benedetti, G, Jensen, M-B, Gelber, S, Del Grande, M, Ignatiadis, M, de Azambuja, E, Paesmans, M, Peccatori, FA & Azim, HA 2018, 'Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status' National Cancer Institute. Journal (Online), bind 110, nr. 4, s. 426-429. https://doi.org/10.1093/jnci/djx206

APA

CBE

Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, Jensen M-B, Gelber S, Del Grande M, Ignatiadis M, de Azambuja E, Paesmans M, Peccatori FA, Azim HA. 2018. Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. National Cancer Institute. Journal (Online). 110(4):426-429. https://doi.org/10.1093/jnci/djx206

MLA

Vancouver

Author

Lambertini, Matteo ; Kroman, Niels ; Ameye, Lieveke ; Cordoba, Octavi ; Pinto, Alvaro ; Benedetti, Giovanni ; Jensen, Maj-Britt ; Gelber, Shari ; Del Grande, Maria ; Ignatiadis, Michail ; de Azambuja, Evandro ; Paesmans, Marianne ; Peccatori, Fedro A ; Azim, Hatem A. / Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status. I: National Cancer Institute. Journal (Online). 2018 ; Bind 110, Nr. 4. s. 426-429.

Bibtex

@article{120f8967514c405b8f1ff4065f2bd0fd,
title = "Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status",
abstract = "Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95{\%} confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95{\%} CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95{\%} CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95{\%} CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.",
keywords = "Journal Article",
author = "Matteo Lambertini and Niels Kroman and Lieveke Ameye and Octavi Cordoba and Alvaro Pinto and Giovanni Benedetti and Maj-Britt Jensen and Shari Gelber and {Del Grande}, Maria and Michail Ignatiadis and {de Azambuja}, Evandro and Marianne Paesmans and Peccatori, {Fedro A} and Azim, {Hatem A}",
note = "{\circledC} The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.",
year = "2018",
doi = "10.1093/jnci/djx206",
language = "English",
volume = "110",
pages = "426--429",
journal = "National Cancer Institute. Journal (Online)",
issn = "1460-2105",
publisher = "Oxford University Press",
number = "4",

}

RIS

TY - JOUR

T1 - Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status

AU - Lambertini, Matteo

AU - Kroman, Niels

AU - Ameye, Lieveke

AU - Cordoba, Octavi

AU - Pinto, Alvaro

AU - Benedetti, Giovanni

AU - Jensen, Maj-Britt

AU - Gelber, Shari

AU - Del Grande, Maria

AU - Ignatiadis, Michail

AU - de Azambuja, Evandro

AU - Paesmans, Marianne

AU - Peccatori, Fedro A

AU - Azim, Hatem A

N1 - © The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

PY - 2018

Y1 - 2018

N2 - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

AB - Safety of pregnancy in women with history of estrogen receptor (ER)-positive breast cancer remains controversial. In this multicenter case-control study, 333 patients with pregnancy after breast cancer were matched (1:3) to 874 nonpregnant patients of similar characteristics, adjusting for guaranteed time bias. Survival estimates were calculated using the Kaplan-Meier analysis; groups were compared with the log-rank test. All reported P values were two-sided. At a median follow-up of 7.2 years after pregnancy, no difference in disease-free survival was observed between pregnant and nonpregnant patients with ER-positive (hazard ratio [HR] = 0.94, 95% confidence interval [CI] = 0.70 to 1.26, P = .68) or ER-negative (HR = 0.75, 95% CI = 0.53 to 1.06, P = .10) disease. No overall survival (OS) difference was observed in ER-positive patients (HR = 0.84, 95% CI = 0.60 to 1.18, P = .32); ER-negative patients in the pregnant cohort had better OS (HR = 0.57, 95% CI = 0.36 to 0.90, P = .01). Abortion, time to pregnancy, breastfeeding, and type of adjuvant therapy had no impact on patients' outcomes. This study provides reassuring evidence on the long-term safety of pregnancy in breast cancer survivors, including those with ER-positive disease.

KW - Journal Article

U2 - 10.1093/jnci/djx206

DO - 10.1093/jnci/djx206

M3 - Journal article

VL - 110

SP - 426

EP - 429

JO - National Cancer Institute. Journal (Online)

JF - National Cancer Institute. Journal (Online)

SN - 1460-2105

IS - 4

ER -

ID: 52341549